Business
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced positive interim results from the randomized, first-line Phase 2 portion of the HexAgon study. The trial evaluated the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-line patients
About this update from Inhibrx Biosciences, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab combination achieved a cORR of 44.0% versus 21.4% with pembrolizumab alone, representing a 22.6% absolute increase in cORR.","length":325,"tagName":"p"}]},{"val":[{"type":"text","content":"Superior depth of response: Responding patients in the combination arm demonstrated deeper tumor reductions overall, with the majority achieving target lesion shrinkage exceeding 50%; notably, three patients achieved a complete radiographic response.","length":250,"tagName":"p"}]},{"val":[{"type":"text","content":"Up to 15-fold mean increase in systemic T-Cell expansion: Peripheral blood analysis showed robust CD8+ and CD4+ T-cell proliferation in combination-treated patients, providing mechanistic support for the observed clinical activity.","length":231,"tagName":"p"}]},{"val":[{"type":"text","content":"Manageable safety profile: The combination demonstrated a manageable preliminary safety profile consistent with that expected from an immunotherapy combination.","length":160,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":966,"olType":false},{"type":"text","content":"SAN DIEGO, May 11, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced positive interim results from the randomized, first-line Phase 2 portion of the HexAgon study. The trial evaluated the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-line patients with treatment-naïve, PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).","length":692,"tagName":"p"},{"type":"image","alt":"Inhibrx, Inc. logo (PRNewsfoto/Inhibrx, Inc.)","displaySize":"","headline":null,"caption":"Inhibrx, Inc. logo (PRNewsfoto/Inhibrx, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":133,"url":"https://media.zenfs.com/en/prnewswire.com/fae7441a9e255131c816a20f83e3312...